Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3707997 | 0.85 | GHSR (0.46) | CNR2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3703214 | 0.85 | GHSR (0.46) | CNR2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3703216 | 0.85 | GHSR (0.46) | CNR2SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL3700170 | 0.82 | CNR2 (0.43) | CNR2ALDH1A1TAAR1GRM2GAA | |
| Trifluoroacetic Acid SCHEMBL8924050 | 0.78 | GHSR (0.51) | GAA | |
| SCHEMBL8933294 | 0.73 | ALDH1A1 (0.45) | SLC6A2SLC6A3SLC6A4ALDH1A1POLB | |
| SCHEMBL6601160 | 0.73 | ALDH1A1 (0.45) | SLC6A2SLC6A3SLC6A4ALDH1A1POLB | |
| SCHEMBL5799815 | 0.70 | ALDH1A1 (0.68) | SLC6A2SLC6A3SLC6A4ALDH1A1POLB | |
| SCHEMBL3698838 | 0.69 | CYP1A2 (0.42) | CNR2ALDH1A1TAAR1GRM2CYP19A1 | |
| SCHEMBL17887234 | 0.66 | ACP3 (0.51) | SLC6A2SLC6A3SLC6A4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CNR2 80/4885SLC6A2 837/4885SLC6A3 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.